Bayer proposes higher-than-expected dividend; J&J takes $100M charge on Venezuelan currency;

@FiercePharma: Teva UK pulls batches of generic Clarinex on impurities in tablets. More | Follow @FiercePharma

@EricPFierce: Capsule maker Qualicaps expanding in NC as it transitions to new ownership. News | Follow @EricPFierce

@AlisonBFierce: Dynavax will shoot for a limited approval of hep B vaccine Heplisav. The FDA nixed the product over safety issues. Report | Follow @AlisonBFierce

> Bayer plans a dividend of €1.90 ($2.51) per share, higher than the €1.82 ($2.38) expected by analysts. Report

> Johnson & Johnson ($JNJ) will take a $100 million charge against first-quarter profits because of Venezuela's currency devaluation. Report

> Amarin ($AMRN) asked the FDA to approve a new use for its blood-lipid treatment Vascepa, derived from fish oil. Release

> Fresenius Kabi's injectable drugs business is giving its parent company a boost; Fresenius SE expects 2013 profits to top €1 billion ($1.31 billion) on the unit's growth. Report

> Nestlé's health science unit bought the "medical foods" firm Pamlab, which makes products for patients with conditions such as diabetes, dementia and depression. Report

> Chemerix tapped former Glaxo Holdings CEO Ernest Mario to be chairman of the board. Report

> Mylan ($MYL) launched its version of AbbVie's ($ABBV) Tricor, a cholesterol fighter known generically as fenofibrate. Report

Medical Device News

 @FierceMedDev: NeuroPace wins FDA panel vote for epilepsy implant. More | Follow @FierceMedDev

 @MarkHFierce: A blood Dx to determine suicide risk? It's possible, and researchers will have a test ready for trials in a year. Story | Follow @MarkHFierce

 @DamianFierce: J&J has to fork over $3.4M in its first vaginal mesh verdict. Roughly 2,100 more lawsuits to go. Report | Follow @DamianFierce

> Abbott lops off another 450 jobs at stent plant. Article

> Mindray milestone: $1B in revenue in 2012. Item

> TearScience wins $70M funding commitment for dry eye device. Story

Biotech News

 @FierceBiotech: AstraZeneca claims PhIII sweep for OIC drug as CV concerns linger. News | Follow @FierceBiotech

@JohnCFierce: Officials prepare to dismantle patent rules that stifle drug R&D. Report | Follow @JohnCFierce

@RyanMFierce: Miami biotech Brickell revealed $7M B round for dermatology drug development. Florida a good spot for this company? Release | Follow @RyanMFierce

> Sanofi's Zerhouni, analysts warn sequestration could cripple R&D. Article

> Cosmetics group leads $7M round for dermatology upstart Brickell. Story

Biotech Research News

@EmilyMFierce: Retargeted bird virus could provide new treatment for prostate cancer. News | Follow @EmilyMFierce

> Therapeutic could heal wounds faster. Story

> New drug combo stops head and neck cancer in mice. Report

> Facebook, Google founders award $33M to life scientists. Item

> Obama administration plans brain-mapping project. More

Pharma Manufacturing News

> Teva repeats recall after getting batch numbers wrong. More

> Affymax explores manufacturing for ties to fatal drug reactions. Story

> Qualicaps expanding plant as Mitsubishi takes ownership. News

> Manufacturing continues to undercut Ranbaxy. Article

And Finally... Just one week of poor sleep can cause genetic changes that might lead to disease. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.